Nurse-led Alcohol Brief Intervention Plus Mobile Personalized Chat-based Support on Reducing Alcohol Use in University Students: a Pragmatic Randomized Controlled Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Alcohol Misuse
- Sponsor
- The University of Hong Kong
- Enrollment
- 770
- Locations
- 1
- Primary Endpoint
- Amount of alcohol consumption per week (gram/week) at 6-month follow-up
- Last Updated
- 4 years ago
Overview
Brief Summary
This study aims to assess the effect of personalized support using instant messaging application on alcohol drinking reduction in university students proactively recruited from universities in Hong Kong.
Detailed Description
The government has promoted Hong Kong as the Asian's wine hub with zero alcohol tax (ethanol ≤30%) since 2008, which causes dramatic increases in alcohol drinking and binge drinking rates. Alcohol use in youth is the leading cause of disability adjusted life-years loss. Most adult drinkers start drinking at age 18-21. Evidence shows that alcohol brief intervention (ABI) is effective reducing hazardous and harmful alcohol use in university students. The proposed trial aims to enhance the ABI by incorporating information communication technologies (ICTs) such as instant messaging (IM) Apps (e.g. WhatsApp and WeChat) to provide personalized, real-time chat-based support led by nurses. The aims of study are as follows: 1. To determine the main effect of the Intervention vs. Control group on alcohol consumption per week at 6-month (Primary) 2. To assess the effects on alcohol consumption per week at 12-month, AUDIT scores at 6 and 12-month, perceived usefulness of IM app at 12-month, intention to use IM app to reduce/quit drinking at 12-month, number of standard drinks, episode of binge drinking, episode of heavy drinking, planned drinking, Academic Role Expectation and Alcohol Scale, Alcohol Problems Scale, Patient Health Questionnaire 4-item, Perceived Stress Scale 4-item, Covid-19 related drinking behavioral changes, and self-efficacy to reduce/quit drinking at 6-month and 12-month 3. To identify mediators between intervention and outcomes to inform the potential mechanisms 4. To qualitatively explore experience on the interventions for reducing alcohol use and related harms
Investigators
Dr. Wang Man-Ping
Associate Professor
The University of Hong Kong
Eligibility Criteria
Inclusion Criteria
- •Student aged ≥18 years from local universities in Hong Kong
- •Able to read and communicate in Chinese (Cantonese or Mandarin)
- •Likely to stay in Hong Kong for most of the time in the next 12 months
- •Using IM Apps (WhatsApp or WeChat) installed on a smartphone
- •Baseline AUDIT screening score ≥8
Exclusion Criteria
- •Having a history of psychiatric/psychological disease or currently on regular psychotropic medications
- •Currently participating in treatments or programmes on reducing alcohol use
Outcomes
Primary Outcomes
Amount of alcohol consumption per week (gram/week) at 6-month follow-up
Time Frame: 6-month after baseline
Assessed by unit in gram and compare the alcohol consumption between intervention and control group at 6-month after baseline.
Compare the primary outcome using intention-to-treat (ITT), per-protocol (PP) and as-treated (AP) analysis with Compliance Average Causal Effect (CACE) analysis
Time Frame: 6-month after baseline
To estimate large, moderate and null (same as the control) treatment effects and check whether ITT, AP and PP analysis estimates are biased compared with CACE estimates (alcohol consumption per week at 6-month follow-up)
Secondary Outcomes
- AUDIT scores at 12-month follow-up(12-month after baseline)
- Episode of heavy drinking in the past 30-day at 6-month follow up(at 6 -month after baseline)
- Episode of binge drinking in the past 30-day at 12-month follow up(at 12-month after baseline)
- Planned drinking measured in the coming 30-day at 6-month follow up(at 6-month after baseline)
- Planned drinking measured in the coming 30-day at 12-month follow up(at 12-month after baseline)
- Alcohol Problems Scale at 12-month follow-up(at 12- month after baseline)
- Patient Health Questionnaire 4-item (PHQ-4) at 12-month(at 12-month after baseline)
- Amount of alcohol consumption per week (gram/week) at 12-month follow-up(12-month after baseline)
- AUDIT scores at 6-month follow-up(6-month after baseline)
- Number of standard drinks (10g of alcohol) per week at 6-month follow-up(6-month after baseline)
- Number of standard drinks (10g of alcohol) per week at 12-month follow-up(12-month after baseline)
- Episode of binge drinking in the past 30-day at 6-month follow up(at 6-month after baseline)
- Self-efficacy to reduce/quit drinking at 12-month(at 12-month after baseline)
- Covid-19 related drinking behavioral changes at 6-month(at 6-month)
- Episode of heavy drinking in the past 30-day at 12-month follow up(at 12-month after baseline)
- Academic Role Expectation and Alcohol Scale at 12-month follow-up(at 12-month after baseline)
- Mediation analysis of variables at 6-month on weekly amount of alcohol consumption at 12-month(at 12- month after baseline)
- Content analysis of IM Apps conversation using alcohol BCT taxonomy(at 12- month after baseline)
- Patient Health Questionnaire 4-item (PHQ-4) at 6-month(at 6-month after baseline)
- Perceived Stress Scale 4-item (PSS-4) at 12-month(at 12-month after baseline)
- Perceived usefulness of IM app intervention at 12-month(at 12-month after baseline)
- Covid-19 related drinking behavioral changes at baseline(at baseline)
- Covid-19 related drinking behavioral changes at 12-month(at 12-month)
- Academic Role Expectation and Alcohol Scale at 6-month follow-up(at 6-month after baseline)
- Perceived Stress Scale 4-item (PSS-4) at 6-month(at 6-month after baseline)
- Self-efficacy to reduce/quit drinking at 6-month(at 6-month after baseline)
- Alcohol Problems Scale at 6-month follow-up(at 6-month after baseline)
- Subgroup analysis of baseline intention to quit/reduce drinking(at 12- month after baseline)
- Intention to continue using IM app intervention at 12-month(at 12-month after baseline)